describe uses of growth hormone and somatropin in different conditions with dose and rationality
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Searching PubMed
"growth hormone" AND "somatropin" AND therapy
Finding Sources
Reading File
Reading File
I now have comprehensive data from multiple authoritative textbooks. Here is a detailed synthesis:
Growth Hormone (Somatropin) — Uses, Doses, and Rationale
Overview
Somatropin is recombinant human growth hormone (rhGH) whose sequence matches native GH. It acts through GH receptors to stimulate hepatic production of insulin-like growth factor-1 (IGF-1), which mediates most of its anabolic and growth-promoting effects. Administered subcutaneously (bioavailability ~70%), it has a plasma half-life of only ~20 minutes but a much longer biological half-life, allowing once-daily dosing in most preparations. The evening is the preferred administration time to mimic the physiologic nocturnal GH surge.
FDA-Approved Indications
1. GH Deficiency in Children (Pituitary Dwarfism)
Rationale: GH is essential for linear bone growth via IGF-1. Deficiency causes proportionate short stature, delayed bone maturation, increased central adiposity, and hypoglycemia in infants. Since GH stimulates chondrocyte proliferation in open epiphyseal plates, replacement restores normal growth velocity.
Dose:
- Somatropin: 20–35 μg/kg/day SC, given in 6–7 divided daily doses (or once daily at bedtime)
- At puberty, dose is often increased to 70 μg/kg/day while monitoring serum IGF-1 and IGFBP-3 (target: no more than +2 SD above upper limit of normal)
- Lonapegsomatropin (long-acting, once-weekly): 0.24 mg/kg/week — now preferred over daily somatropin
Monitoring: Average growth of 9–10 cm in year 1, then 6–7 cm/year for next 2 years. Check thyroid function if growth slows. Treat until growth velocity <2.0–2.5 cm/year or target height reached. Discontinue when epiphyses close.
2. GH Deficiency in Adults
Rationale: Adult-onset GHD (from surgery, trauma, radiation, or pituitary disease) causes generalized obesity, reduced lean muscle mass, asthenia, reduced bone mineral density, dyslipidemia, impaired cardiac output, and diminished quality of life. GH replacement reverses many of these metabolic derangements.
Dose:
- Somatropin: Start at 150–300 μg/day SC (or 2.0–5.0 μg/kg/day), titrate by 100–200 μg/day increments every 2 months targeting mid-normal serum IGF-1 for age
- Women on oral estrogen require higher doses (typically 3.0 μg/kg/day for premenopausal or oral-estrogen users) due to first-pass hepatic blunting of GH action
- Somapacitan (long-acting weekly analog): Start at 1.5 mg/week SC; increase by 0.5–1.5 mg increments up to maximum 8 mg/week
- Evening administration preferred to mimic physiologic diurnal rhythm
3. Turner Syndrome
Rationale: Girls with 45,X karyotype have short stature despite normal GH levels due to haploinsufficiency of the SHOX gene and partial GH resistance. Exogenous GH overcomes receptor resistance and promotes linear growth. Combined judiciously with low-dose estrogen to optimize both height and secondary sexual development.
Dose: 50–67 μg/kg/day SC (higher than standard GH-deficiency dose to overcome partial resistance)
Expected benefit: Average increase in adult height of 10–15 cm (4–6 inches) vs. untreated controls.
4. Noonan Syndrome
Rationale: Autosomal dominant syndrome with short stature, characteristic facies, and cardiac defects. Growth failure is multifactorial; GH therapy improves height similarly to Turner syndrome due to partial GH resistance.
Dose: 50–67 μg/kg/day SC
5. Prader-Willi Syndrome (PWS)
Rationale: PWS is an autosomal dominant disorder with GH deficiency, severe obesity, and carbohydrate intolerance. GH therapy reduces body fat, increases lean mass, linear growth, and energy expenditure. However, this indication requires careful patient selection.
Dose: 25–50 μg/kg/day SC
Critical contraindication: GH is contraindicated in PWS patients who are severely obese or have severe respiratory impairment — sudden deaths have occurred due to increased risk of asphyxia/sleep apnea.
6. Chronic Renal Insufficiency (Pre-transplant)
Rationale: CRI suppresses the GH-IGF-1 axis and causes uremia-related growth failure in children. Exogenous GH can restore growth velocity by overcoming IGF-1 resistance at the tissue level.
Dose: 50 μg/kg/day SC (pre-transplant); discontinued after renal transplant with adequate function.
7. SHOX Gene Deficiency
Rationale: Haploinsufficiency of the short stature homeobox gene (SHOX) on the X chromosome causes short stature. GH therapy increases height through IGF-1-mediated chondrogenesis.
Dose: 50 μg/kg/day SC
8. Small for Gestational Age (SGA) with Failure to Catch Up
Rationale: Most SGA infants catch up by age 2, but ~10–15% do not. These children often have relative GH resistance. Exogenous GH promotes catch-up growth when administered before epiphyseal fusion.
Criteria: Height remains >2 SD below normal at age 2 years
Dose: 35–70 μg/kg/day SC
9. Idiopathic Short Stature (ISS)
Rationale: A controversial but FDA-approved use. ISS is defined as height ≥2.25 SD below mean for age and sex with no identifiable cause. GH therapy modestly increases final adult height.
Dose: 50–67 μg/kg/day SC
Expected benefit: Average adult height gain of only 4–7 cm after many years of treatment, at significant cost ($5,000–$40,000/year). The risk-benefit ratio is debated.
10. AIDS-Associated Wasting/Cachexia
Rationale: HIV-associated wasting (involuntary weight loss >10% with diarrhea or weakness) involves loss of lean body mass driven by catabolic cytokines and poor nutritional state. GH has net anabolic effects — it promotes nitrogen retention, increases lean body mass, and improves physical endurance by stimulating protein synthesis via IGF-1.
Dose: GH is approved at 4–6 mg/day SC for HIV-associated wasting
Monitoring: Regular assessment of lean/fat mass and quality-of-life metrics.
11. Short Bowel Syndrome (SBS)
Rationale: After extensive intestinal resection, GH stimulates GI epithelial adaptation, increasing intestinal villous height and improving absorptive surface area. It is used in conjunction with glutamine (an intestinal fuel) and specialized nutritional support to reduce dependence on total parenteral nutrition (TPN).
Approval: FDA-approved in 2004 for TPN-dependent SBS patients
Dose: 0.1 mg/kg/day SC (up to 8 mg/day) for a limited course
Caveat: Clinical benefits have mostly been short-lived in published studies.
Long-Acting Formulations
| Agent | Mechanism | Dose | Indication |
|---|---|---|---|
| Lonapegsomatropin | PEGylated GH (weekly) | 0.24 mg/kg/week SC | Pediatric GHD (preferred over daily somatropin) |
| Somapacitan | Albumin-binding GH analogue (weekly) | 1.5–8 mg/week SC | Adult GHD |
Off-Label and Controversial Uses
| Use | Evidence | Comment |
|---|---|---|
| Anti-aging | Unsubstantiated | Risks (carpal tunnel, edema, glucose intolerance) outweigh benefits; paradoxically, animal data show GH/IGF-1 signaling shortens lifespan |
| Athletic performance enhancement | No proven benefit | Banned by International Olympic Committee |
| Fibromyalgia | Weak/insufficient | Some GHD features overlap with fibromyalgia; trials have been small |
Adverse Effects
| Category | Effects |
|---|---|
| Children | Pain at injection site, pseudotumor cerebri (papilledema, headache), slipped capital femoral epiphysis, scoliosis progression, edema, hyperglycemia |
| Adults | Peripheral edema, carpal tunnel syndrome, arthralgias, myalgias (especially hands/wrists), glucose intolerance — usually dose-dependent and resolve with dose reduction |
| Metabolic | Increased cortisol inactivation (can unmask adrenal insufficiency); reduced insulin sensitivity (adjust diabetes medications); increased CYP450 activity (may lower levels of co-administered drugs) |
Key Contraindications
- Active malignancy (absolute contraindication)
- Closed epiphyses in children (for growth purposes)
- Proliferative diabetic retinopathy or severe non-proliferative diabetic retinopathy
- Severely obese or respiratory-impaired patients with Prader-Willi syndrome
- Acute critical illness (post-cardiac/abdominal surgery, severe trauma, acute respiratory failure)
- First year post-treatment of pediatric CNS tumors (leukemia, medulloblastoma)
Summary Table
| Condition | Population | Daily Dose | Key Rationale |
|---|---|---|---|
| GH deficiency | Children | 20–35 μg/kg/day SC | Replace deficient GH; restore growth |
| GH deficiency (puberty) | Adolescents | Up to 70 μg/kg/day SC | Overcome pubertal GH surge requirement |
| GH deficiency | Adults | 150–300 μg/day (start) | Restore metabolic health, body composition |
| Turner syndrome | Girls | 50–67 μg/kg/day SC | Overcome SHOX/GH resistance |
| Noonan syndrome | Children | 50–67 μg/kg/day SC | Overcome partial GH resistance |
| Prader-Willi syndrome | Children | 25–50 μg/kg/day SC | Decrease fat, increase lean mass |
| Chronic renal insufficiency | Children (pre-transplant) | ~50 μg/kg/day SC | Overcome uremic IGF-1 resistance |
| SGA (no catch-up by age 2) | Children | 35–70 μg/kg/day SC | Promote catch-up growth |
| Idiopathic short stature | Children | 50–67 μg/kg/day SC | Modest height gain (controversial) |
| AIDS wasting | Adults | 4–6 mg/day SC | Anabolic effect; increase lean body mass |
| Short bowel syndrome | Adults on TPN | ~0.1 mg/kg/day SC | Stimulate GI epithelial adaptation |
Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics; Katzung's Basic and Clinical Pharmacology, 16th Ed.; Lippincott Illustrated Reviews: Pharmacology; Goldman-Cecil Medicine
This is a shared conversation. Sign in to Orris to start your own chat.